Welcome to our dedicated page for Taysha Gene Therapies SEC filings (Ticker: TSHA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Taysha Gene Therapies, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage biotechnology company developing AAV-based gene therapies for severe monogenic CNS diseases. Its 8-K reports furnish financial results, business highlights, TSHA-102 clinical and regulatory updates, program-rights announcements, and exhibits tied to company press releases.
The filing record also includes proxy materials for annual stockholder meetings, director elections and voting matters, as well as material definitive agreement disclosures involving common-stock sales arrangements. Cover-page disclosures identify TSHA common stock, par value and Nasdaq listing status, while proxy filings provide formal governance and stockholder-meeting information.
RA Capital and affiliated persons reported a near-10% position in Taysha Gene Therapies (TSHA). The filing shows each Reporting Person beneficially owns 25,345,988 shares, representing 9.99% of the class as of June 30, 2025, limited by a Beneficial Ownership Blocker in pre-funded warrants. The Fund directly holds 23,555,648 shares and pre-funded warrants exercisable for up to 52,134,718 shares, but cannot exercise warrants that would raise ownership above the 9.99% threshold. RA Capital is the investment adviser with sole voting and dispositive power delegated by the Fund; Dr. Kolchinsky and Mr. Shah are identified as controlling persons.
RTW Investments, LP and Roderick Wong report beneficial ownership of 25,183,287 shares of Taysha Gene Therapies, Inc., representing approximately 9.99% of the outstanding common stock. The reported holdings reflect shared voting and shared dispositive power over the 25.18 million shares and include warrants to purchase 161,703 shares that were counted at their maximum exercisable amount but which cannot be exercised to increase beneficial ownership above the 9.99% threshold. The filing states these shares are held by RTW-managed funds and that RTW Master Fund Ltd. has the right to receive dividends or sale proceeds for more than 5% of the class. The filing is submitted on a Schedule 13G amendment and characterizes the position as held in the ordinary course of business.
Taysha Gene Therapies reported a strengthened balance sheet after a May 2025 underwritten offering that generated approximately $215.6 million in net proceeds, increasing cash and cash equivalents to $312.8 million and total assets to $333.3 million as of June 30, 2025. The company reported a net loss of $48.4 million for the six months ended June 30, 2025, which translates to a loss per share of $0.17 on a weighted-average share base of 283.7 million; research and development and general and administrative expenses totaled $52.5 million for the six-month period.
The company recognized $4.3 million of revenue related to Rett research and development activities in the six months, and deferred revenue related to the Astellas option totaled $5.5 million as of June 30, 2025. Taysha recorded the Trinity term loan at fair value and continues to mark the loan and a related success fee to market; the company stated it believes existing cash will be sufficient to fund planned operations for at least twelve months from issuance of these financial statements.
Taysha Gene Therapies disclosed that it furnished a press release reporting financial results and business highlights for the quarter ended June 30, 2025. The filing states the press release is included as Exhibit 99.1 and that the cover page interactive XBRL file is provided as Exhibit 104. The company notes the information in Item 2.02 (including Exhibit 99.1) is being furnished and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
This report identifies the exhibits attached but does not present the detailed financial figures within the body of the 8-K itself; investors should consult Exhibit 99.1 for the full results and disclosures.
Morgan Stanley and subsidiary Morgan Stanley Capital Services LLC filed Amendment No. 1 to Schedule 13G reporting a passive stake in Taysha Gene Therapies, Inc. (TSHA) as of 30 Jun 2025.
The filing discloses 16,858,644 common shares, equal to 6.7 % of the outstanding class (CUSIP 877619106). Voting and dispositive authority are entirely shared: 16,651,747 shares with shared voting power and 16,858,644 shares with shared dispositive power; neither entity claims sole authority. Morgan Stanley is classified as a holding company/control person, while Morgan Stanley Capital Services LLC is a broker-dealer. The securities are held in the ordinary course of business with no intent to influence control of the issuer.
The Schedule 13G filed on 27 June 2025 discloses that The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have acquired beneficial ownership of 12,748,968 shares of Taysha Gene Therapies, Inc. (TSHA) common stock. The position represents 5.1 % of TSHA’s outstanding shares, crossing the 5 % reporting threshold under Section 13(d) of the Securities Exchange Act.
All voting and dispositive authority over the shares is reported as shared; neither entity claims sole authority. The filing is on Schedule 13G, indicating a passive investment rather than an effort to influence control, as confirmed by the Item 10 certification.
Goldman Sachs & Co. LLC is classified as a broker-dealer, other organization, and investment adviser, while The Goldman Sachs Group, Inc. is identified as a holding company/control person. No additional group members or activist exhibits are included.
The disclosure confirms meaningful institutional ownership by a globally recognized financial institution, potentially improving share liquidity and lending credibility to TSHA. However, because it is a passive filing, it does not imply forthcoming strategic or operational changes at the issuer.